
CLAIMS

1. Use of a taxane and a RXR agonist, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for treating a $Her2^+$ cancer in a patient in need thereof, wherein the RXR agonist is of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons, and wherein the taxane and RXR agonist, or a pharmaceutically-acceptable salt thereof, are to be administered to the patient.

2. The use of claim 1, wherein the patient had previously been treated with a taxane but not with the RXR agonist and had obtained less than a complete response.

3. The use of claim 1, wherein the patient had previously been treated with the RXR agonist, but not the taxane.

4. Use of a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for treating a $Her2^+$ cancer in a patient in need thereof, wherein the RXR agonist or pharmaceutically acceptable salt thereof is to be administered with means for binding tubulin and inhibiting microtubule disassembly, means for blocking metaphase spindle formation, or means for inducing apoptosis by blocking Bcl-2-mediated inhibition of apoptosis.

5. Use of taxane in the manufacture of a medicament for treating a $Her2^+$ cancer in a patient in need thereof, wherein taxane is to be administered with means for activating RXR/Nurr1 heterodimeric receptors or rexinoid means for inhibiting tumor growth.

6. The use of any one of claims 1-5, wherein a thyroid hormone is to be further administered to the patient .

7. The use of any one of claims 1-6, wherein the RXR agonist of Formula 1 is the compound of Formula II:



(Formula II).

8. The use of any one of claims 1-3 or 5, wherein the taxane is paclitaxel.

9. The use of any one of claims 1-3 or 5, wherein the taxane is docetaxel.

10. The use of any one of claims 1-9, wherein the $Her2^+$ cancer is gastroesophageal cancer, ovarian cancer, stomach cancer, adenocarcinoma of the lung, uterine cancer, or salivary duct carcinoma.

11. The use of any one of claims 1-9, wherein the $Her2^+$ cancer is breast cancer.

12 The use of any one of claims 1-3 and 5-11, wherein the combination of the taxane and RXR agonist has a growth inhibitory effect that is greater than the additive growth inhibitory effects of each of the two agents alone.

13. The use of any one of claims 1-12, wherein an additional anticancer agent is to be further administered to the patient.